The VITAL study: A randomized, double-blind, placebo-controlled, global, phase III study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. Liedtke, M., Merlini, G., Landau, H., Comenzo, R., Seldin, D. C., Weiss, B. M., Zonder, J. A., Walling, J., Kinney, G., Koller, M., Gertz, M. A. AMER SOC CLINICAL ONCOLOGY. 2015

View details for Web of Science ID 000358036904876